Rising Star: Mayer Brown's Andrew Calica

Law360, New York (April 2, 2015, 4:12 PM EDT) -- Mayer Brown LLP partner Andrew Calica has secured a string of game-changing victories in litigation implicating branded-drug maker UCB Inc. over alleged neurological disorders caused by its heartburn drug Reglan, landing him a spot among Law360’s Rising Stars list of top attorneys under 40.

In 2009, when the U.S. Food and Drug Administration added a black box warning cautioning users of metoclopramide — the drug contained in Reglan — that usage exceeding 12 weeks could cause neurological problems, Calica was on a team of Mayer Brown attorneys who were already representing UCB. After the FDA's decision, work for UCB suddenly became...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS